WO2007017705A1 - Process for the preparation of azetidinones - Google Patents

Process for the preparation of azetidinones Download PDF

Info

Publication number
WO2007017705A1
WO2007017705A1 PCT/IB2005/002393 IB2005002393W WO2007017705A1 WO 2007017705 A1 WO2007017705 A1 WO 2007017705A1 IB 2005002393 W IB2005002393 W IB 2005002393W WO 2007017705 A1 WO2007017705 A1 WO 2007017705A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
group
benzyl
alcohol
base
Prior art date
Application number
PCT/IB2005/002393
Other languages
French (fr)
Inventor
Mangesh Shivram Sawant
Biju Kumar Gopinathen Pillai
Shekhar Bhaskar Bhirud
Krishnadatt Sharma
Original Assignee
Glenmark Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Limited filed Critical Glenmark Pharmaceuticals Limited
Priority to PCT/IB2005/002393 priority Critical patent/WO2007017705A1/en
Publication of WO2007017705A1 publication Critical patent/WO2007017705A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams

Definitions

  • the present invention generally relates to an improved process for the preparation of azetidinones.
  • the present invention relates to a process for the preparation of azetidinones such as ezetimibe (also known as l-(4-fluorophenyl)-3(R)-[3-(4- fiuorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone) of Formula I:
  • ezetimibe also known as l-(4-fluorophenyl)-3(R)-[3-(4- fiuorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone
  • Ezetimibe is sold under the commercial name Zetia ® .
  • Ezetimibe is a lipid- lowering compound in the class of azetidinones that selectively inhibits the intestinal absorption of cholesterol and related phytosterols. Ezetimibe acts by diminishing the absorption of dietary cholesterol through the intestines by getting localized in the brush border of small intestinal endocytes and blocks the uptake of cholesterol.
  • Ezetimibe is ordinarily used as an adjunctive therapy to a diet for the reduction of elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B (Apo B) in patients with primary (heterozygous familial and non-familial) hypercholesterolemia.
  • total-C total cholesterol
  • LDL-C low-density lipoprotein cholesterol
  • Apo B apolipoprotein B
  • U.S. Patent No. 5,631,365 discloses a process for preparing ezetimibe.
  • the process for preparing ezetimibe includes: (1) treating a lactone with a strong base in an anhydrous organic solvent; (2) reacting the product of (1) with an imine; (3) quenching the reaction with an acid; and (4) removing any necessary protecting groups.
  • Several drawbacks are associated with the processes of the prior art.
  • pyrophoric bases such as n-butyl lithium and a metalamide, e.g., LDA
  • low temperatures e.g., below -50°C
  • butyl lithium is a hazardous, corrosive reagent which limits its usefulness.
  • step (b) hydrolyzing the protected amide of step (a) with a strong base to provide a protected carboxylic acid of formula V:
  • step (c) reacting an organic halide with the protected carboxylic acid of step (b) and an imine of formula VI:
  • the present invention is directed to a process for preparing a compound of formula I:
  • step (a) of the process of the present invention an alcohol of formula III:
  • R and R can independently be hydrogen, hydrocarbons of from 1 to 20 carbon atoms or
  • R and R together with the nitrogen atom to which they are bonded are joined together to form a substituted or unsubstituted heterocyclic group optionally containing one or more additional heterocyclic atoms.
  • R 1 and R 2 are hydrogen.
  • R and R are independently methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, hexyl, cyclohexyl, heptyl, octyl, 2-ethylhexyl, nonyl, decyl, dodecyl, stearyl, oleyl, phenyl, benzyl, and the like, containing, e.g., up to about 20 carbon atoms, preferably no more than about 18 carbon atoms and more preferably no more than about 12 carbon atoms.
  • R 1 and R 2 together with the nitrogen atom to which they are bonded are joined together to form a heterocyclic compound include substituted or unsubstituted cyclic amines such as pyrrolidines, piperidines, piperazines, morpholines, and the like.
  • R 1 and R 2 can also independently be alkyl groups substituted with one or more heterocyclic substituents.
  • Representative of the starting alcohols of formula III are known in the art.
  • the starting alcohol can be prepared by first amidating p-fluorobenzoyl butyric acid with an amine of the formula HNR 1 R 2 wherein R 1 and R 2 have the aforestated meanings optionally in the presence of a suitable solvent to provide a keto amide of formula II:
  • Suitable amines include, but are not limited to, pyrrolidines such as 2-(2- aminoethyl)-l-methylpyrrolidine, l-(2-aminoethyl)pyrrolidine, and the like; morpholines such as 4-(2-aminoethyl)-morpholine and the like; piperidines such as l-(2-aminoethyl)- piperidine, 4-dimethyl-amino pyridine and the like; piperazines such as l-(2- aminoethyl)piperazine, and the like and mixtures thereof.
  • pyrrolidines such as 2-(2- aminoethyl)-l-methylpyrrolidine, l-(2-aminoethyl)pyrrolidine, and the like
  • morpholines such as 4-(2-aminoethyl)-morpholine and the like
  • piperidines such as l-(2-aminoethyl)- piperidine, 4-dimethyl-amino
  • Suitable amines are (arninoalkyl)alkylamines such as N-alkylethylene diamines, N-alkyl-l,3-propane diamines, and the like.
  • Suitable solvents include, but are not limited to, C 1 to C 4 alcohols such as methanol, ethanol, iso-propanol and butanol, lower ketones such as acetone, amides such as dimethylformamide (“DMF”) and N,N'-carbonyl diimidazole and the like and mixtures thereof.
  • keto amide is reduced to the corresponding alcohol of formula III under conditions well known in the art, for example, by using a reagent such as BH 3 .S(CH 3 ) 2 in the presence of a chiral promoting agent such as, for example, a chiral borane (e.g., (R)-methyl oxazaborilidine).
  • a reagent such as BH 3 .S(CH 3 ) 2
  • a chiral promoting agent such as, for example, a chiral borane (e.g., (R)-methyl oxazaborilidine).
  • Useful protecting groups to provide a protected amide of formula IV include, but are not limited to, aromatic protecting groups such as, for example, benzyl bromide, benzyl chloride and benzyl iodide, and the like. If desired, the reaction can be carried out in the presence of a base to provide a protected amide of formula IV.
  • Useful bases include, but are not limited to, sodium t-butoxide, potassium t-butoxide, diisopropylamide, sodium hydride, potassium hydride, sodium methoxide, potassium methoxide and the like and mixtures thereof.
  • step (b) of the process of the present invention the protected amide of formula IV is hydrolyzed under conditions well known in the art, for example, by hydrolyzing the protected amide with a strong base in an alcoholic solution, e.g., an ethanolic solution, to provide a protected carboxylic acid of formula V.
  • an organic halide e.g., thionyl chloride
  • Suitable protecting groups include, but are not limited to, aromatic protecting groups such as a benzyl containing group, e.g., a substituted or unsubstituted benzyl group as described above.
  • the organic halide is reacted with a mixture of the carboxylic acid of formula V and the imine.
  • Suitable inert organic solvents for use herein can be, for example, a hydrocarbon having from 5 to about 12 carbon atoms such as an aromatic hydrocarbon or an aliphatic hydrocarbon solvent.
  • aromatic hydrocarbons include, but are not limited to, xylene, benzene, toluene, chlorobenzene and the like.
  • the reaction is ordinarily carried out at reflux in the presence of one or more bases.
  • Representative bases for use herein include, but are not limited to, an organic amine, an alkoxide, a hydroxide of an alkali metal or an alkaline earth metal.
  • Specific examples of bases include, but are not limited to, N,N'-diisopropyl ethylamine, triethylamine, sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide.
  • at least two bases are employed in this step.
  • step (d) of the process of the present invention the protecting groups on the azetidinone of the formula VI are removed by methods well known in the art, for example, by hydrogenating an alcoholic solution, e.g., a methanolic solution, of the compound of formula VI with Pd/C under H 2 at a suitable pressure, e.g., a pressure of about 6.5 Kg/cm2, to provide the compound of formula I.
  • an alcoholic solution e.g., a methanolic solution
  • Pd/C e.g., a pressure of about 6.5 Kg/cm2
  • the compound of formula I can be obtained by at least (a) providing an alcohol by first reacting p-fluorobenzoyl butyric acid (2) with morpholine in the presence of N,N'-carbonyl diimidazole (CDI) to form a keto amide (3):
  • step II To a solution of the alcohol prepared in step II (30.Og 5 0.11 mol) in tetrahydrofuran (THF) (240.0 ml) maintained under nitrogen atmosphere, sodium hydride (5.5g, 0.138 mol) was added at a temperature of about O 0 C. Benzyl bromide (20.4g, 0.12 mol) was added slowly to the reaction mass at a temperature of about 0 0 C. After completion of the addition, the reaction mass was stirred for 24 hours at room temperature. After completion of the reaction as determined by TLC, the reaction mass was cooled to O 0 C and water (30.0 ml) was added slowly. The reaction mixture was brought to room temperature and the solvent was distilled off under reduced pressure to get a residue.
  • THF tetrahydrofuran
  • the aqueous layer was extracted with ethyl acetate (2 X 200.0 ml).
  • the ethyl acetate layer was washed with water (200.0 ml) and brine (200.0 ml).
  • the organic layer was dried over anhydrous sodium sulfate.
  • the organic layer was evaporated to yield the carboxylic acid as a liquid (17.Og).
  • reaction mass (307.5 g:3.2 moles) was added.
  • the reaction mass was cooled to a temperature of about 5°C and a suspension of glutaric anhydride (0.86 mol) in fluorobenzene (400.0 ml, 4.3 mol) was added dropwise. After completion of the addition, the reaction mass was brought to room temperature and maintained for 2 hours. On completion of the reaction as determined by NMR, the reaction mass was cooled to a temperature ranging from about 0°C to about 3 0 C and IN HCl (715.0 ml) was added below a temperature of about 20°C. The reaction mixture was poured into 2.3 L of ice- water suspension under stirring and the precipitated solids were filtered out.

Abstract

A process for preparing an azetidinone such as ezetimibe of formula (I) is disclosed using an alcohol of formula (III) as starting material.

Description

PROCESS FOR THE PREPARATION OF AZETIDINONES
BACKGROUND OF THE INVENTION
1. Technical Field
[0001] The present invention generally relates to an improved process for the preparation of azetidinones.
2. Description of the Related Art
[0002] The present invention relates to a process for the preparation of azetidinones such as ezetimibe (also known as l-(4-fluorophenyl)-3(R)-[3-(4- fiuorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone) of Formula I:
Figure imgf000002_0001
[0003] Ezetimibe is sold under the commercial name Zetia®. Ezetimibe is a lipid- lowering compound in the class of azetidinones that selectively inhibits the intestinal absorption of cholesterol and related phytosterols. Ezetimibe acts by diminishing the absorption of dietary cholesterol through the intestines by getting localized in the brush border of small intestinal endocytes and blocks the uptake of cholesterol. Ezetimibe is ordinarily used as an adjunctive therapy to a diet for the reduction of elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B (Apo B) in patients with primary (heterozygous familial and non-familial) hypercholesterolemia.
[0004] U.S. Patent No. 5,631,365 ("the '365 patent") discloses a process for preparing ezetimibe. In the '365 patent, the process for preparing ezetimibe includes: (1) treating a lactone with a strong base in an anhydrous organic solvent; (2) reacting the product of (1) with an imine; (3) quenching the reaction with an acid; and (4) removing any necessary protecting groups. [0005] Several drawbacks are associated with the processes of the prior art. These drawbacks include using pyrophoric bases, such as n-butyl lithium and a metalamide, e.g., LDA, and low temperatures, e.g., below -50°C, which lead to difficulties when trying to prepare ezetimibe on a commercial scale. Further, butyl lithium is a hazardous, corrosive reagent which limits its usefulness.
[0006] Accordingly, there remains a need for improved processes for preparing ezetimibe that eliminates and reduces the drawbacks of the prior art in a convenient and cost efficient manner on a commercial scale.
SUMMARY OF THE INVENTION
[0007] In one embodiment of the present invention, a process for preparing a compound of formula I is provided:
Figure imgf000003_0001
the process comprising
(a) reacting an alcohol of formula III:
Figure imgf000003_0002
wherein R1 and R2 are as described herein, with a protecting group to provide a protected amide of formula IV:
Figure imgf000003_0003
(b) hydrolyzing the protected amide of step (a) with a strong base to provide a protected carboxylic acid of formula V:
Figure imgf000004_0001
(c) reacting an organic halide with the protected carboxylic acid of step (b) and an imine of formula VI:
Figure imgf000004_0002
wherein Prot is a protecting group to provide an azetidinone of formula VII
Figure imgf000004_0003
(d) removing the protecting groups.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0008] The present invention is directed to a process for preparing a compound of formula I:
Figure imgf000004_0004
[0009] In step (a) of the process of the present invention, an alcohol of formula III:
Figure imgf000005_0001
is reacted with a protecting group to provide a protected amide of the formula IV:
Figure imgf000005_0002
R and R can independently be hydrogen, hydrocarbons of from 1 to 20 carbon atoms or
R and R together with the nitrogen atom to which they are bonded are joined together to form a substituted or unsubstituted heterocyclic group optionally containing one or more additional heterocyclic atoms. Preferably, only one of R1 and R2 are hydrogen. Representative examples of R and R are independently methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, hexyl, cyclohexyl, heptyl, octyl, 2-ethylhexyl, nonyl, decyl, dodecyl, stearyl, oleyl, phenyl, benzyl, and the like, containing, e.g., up to about 20 carbon atoms, preferably no more than about 18 carbon atoms and more preferably no more than about 12 carbon atoms. Representative groups in the case where R1 and R2 together with the nitrogen atom to which they are bonded are joined together to form a heterocyclic compound include substituted or unsubstituted cyclic amines such as pyrrolidines, piperidines, piperazines, morpholines, and the like. R1 and R2 can also independently be alkyl groups substituted with one or more heterocyclic substituents. [0010] Representative of the starting alcohols of formula III are known in the art.
See, e.g., U.S. Patent No. 6,207,822. In general, the starting alcohol can be prepared by first amidating p-fluorobenzoyl butyric acid with an amine of the formula HNR1R2 wherein R1 and R2 have the aforestated meanings optionally in the presence of a suitable solvent to provide a keto amide of formula II:
Figure imgf000005_0003
(H). Examples of suitable amines include, but are not limited to, pyrrolidines such as 2-(2- aminoethyl)-l-methylpyrrolidine, l-(2-aminoethyl)pyrrolidine, and the like; morpholines such as 4-(2-aminoethyl)-morpholine and the like; piperidines such as l-(2-aminoethyl)- piperidine, 4-dimethyl-amino pyridine and the like; piperazines such as l-(2- aminoethyl)piperazine, and the like and mixtures thereof. Other useful amines are (arninoalkyl)alkylamines such as N-alkylethylene diamines, N-alkyl-l,3-propane diamines, and the like. Suitable solvents include, but are not limited to, C1 to C4 alcohols such as methanol, ethanol, iso-propanol and butanol, lower ketones such as acetone, amides such as dimethylformamide ("DMF") and N,N'-carbonyl diimidazole and the like and mixtures thereof. Next, the keto amide is reduced to the corresponding alcohol of formula III under conditions well known in the art, for example, by using a reagent such as BH3.S(CH3)2 in the presence of a chiral promoting agent such as, for example, a chiral borane (e.g., (R)-methyl oxazaborilidine).
[0011] Useful protecting groups to provide a protected amide of formula IV include, but are not limited to, aromatic protecting groups such as, for example, benzyl bromide, benzyl chloride and benzyl iodide, and the like. If desired, the reaction can be carried out in the presence of a base to provide a protected amide of formula IV. Useful bases include, but are not limited to, sodium t-butoxide, potassium t-butoxide, diisopropylamide, sodium hydride, potassium hydride, sodium methoxide, potassium methoxide and the like and mixtures thereof.
[0012] In step (b) of the process of the present invention, the protected amide of formula IV is hydrolyzed under conditions well known in the art, for example, by hydrolyzing the protected amide with a strong base in an alcoholic solution, e.g., an ethanolic solution, to provide a protected carboxylic acid of formula V. [0013] In step (c) of the process of the present invention, an organic halide, e.g., thionyl chloride, is reacted with the protected carboxylic acid of formula V and an imine of formula VI:
Figure imgf000006_0001
(VI); wherein Prot is a protecting group in the presence of one or more inert organic solvents to provide the azetidinone of the formula VII. Suitable protecting groups include, but are not limited to, aromatic protecting groups such as a benzyl containing group, e.g., a substituted or unsubstituted benzyl group as described above. Preferably, the organic halide is reacted with a mixture of the carboxylic acid of formula V and the imine. Suitable inert organic solvents for use herein can be, for example, a hydrocarbon having from 5 to about 12 carbon atoms such as an aromatic hydrocarbon or an aliphatic hydrocarbon solvent. Examples of aromatic hydrocarbons include, but are not limited to, xylene, benzene, toluene, chlorobenzene and the like. The reaction is ordinarily carried out at reflux in the presence of one or more bases. Representative bases for use herein include, but are not limited to, an organic amine, an alkoxide, a hydroxide of an alkali metal or an alkaline earth metal. Specific examples of bases include, but are not limited to, N,N'-diisopropyl ethylamine, triethylamine, sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide. Preferably, at least two bases are employed in this step.
[0014] In step (d) of the process of the present invention, the protecting groups on the azetidinone of the formula VI are removed by methods well known in the art, for example, by hydrogenating an alcoholic solution, e.g., a methanolic solution, of the compound of formula VI with Pd/C under H2 at a suitable pressure, e.g., a pressure of about 6.5 Kg/cm2, to provide the compound of formula I.
[0015] In a preferred reaction scheme, the compound of formula I can be obtained by at least (a) providing an alcohol by first reacting p-fluorobenzoyl butyric acid (2) with morpholine in the presence of N,N'-carbonyl diimidazole (CDI) to form a keto amide (3):
Figure imgf000007_0001
and then reducing the keto amide (3) with BH3.S(CH3)2 in the presence of a chiral catalyst (R)-methyl oxazaborilidine to provide an alcohol of formula (4)
Figure imgf000008_0001
(b) reacting the alcohol (4) with a benzyl contaning halide in the presence of sodium hydride to provide a benzyl protected amide (5):
Figure imgf000008_0002
(c) hydrolyzing the benzyl protected amide (5) with a strong base in about 95% ethanol to provide a carboxylic acid (6):
Figure imgf000008_0003
(d) reacting thionyl chloride with a mixture of the carboxylic acid (6) and an imine (7) wherein Ph is phenyl in toluene at reflux in the presence of one or more bases to provide an azetidinone (8):
Figure imgf000008_0004
(d) deprotecting the azetidinone (8) by hydrogenation in the presence of Pd/C to provide an ezetimibe precursor (9); and (e) purifying the ezetimibe precursor (9) to form ezetimibe (10):
Figure imgf000009_0001
[0016] The following examples are provided to enable one skilled in the art to practice the invention and are merely illustrative of the invention. The examples should not be read as limiting the scope of the invention as defined in the claims.
EXAMPLE 1
Step I: Synthesis of the Keto Amide
[0017] A solution of p-fluorobenzoyl butyric acid (50.Og, 0.24 mol) in DMF
(500.0 ml) and N,N'-Carbonyl diimidazole (50.Og, 0.31 mol) was stirred under nitrogen at about room temperature (from about 25°C to about 30°C) for three hours. Morpholine (40.0 ml, 0.46 mol) was added to the reaction mass dropwise. The reaction mass was stirred at a temperature ranging from about 4O0C to about 45 °C for about 10 hours. After completion of the reaction as determined by TLC, the reaction mass was cooled to a temperature ranging from about O0C to about 5°C and adjusted to a pH of about 2.0 with 2N HCl and extracted with ethyl acetate (2 X 500.0 ml). The ethyl acetate layer was washed with saturated sodium bicarbonate solution (200.0 ml), water (200.0 ml) and brine (200.0 ml). The ethyl acetate layer on evaporation gave a residue. The residue on crystallization from ethyl acetate/hexane yielded 55.Og of the keto amide III. [0018] Mp: 54-55°C. IR(Cm'1) :3044, 3061, 1636, 1677, 1599, 1441, 1278, 1241,
1114, 1030, 988, 960. 1H NMR (CDCl3) (δ ppm): 2.1(2H), 2.4(2H), 3.1(2H), 3.5(2H), 3.7(6H), 7.1(2H), 8.0(2H). (M+l):280.2 EXAMPLE 2
Step II: Synthesis of the Alcohol
[0019] To a solution of borane dimethyl sulfide (16.0 ml, 0.17 mol) in dichloromethane (100 ml) maintained at a temperature of -5°C under nitrogen atmosphere was added (R)-methyl oxazaborilidine catalyst in toluene (IM, 8.0 ml, 0.0078 mol) and maintained for 15 minutes. To the above mixture, a solution of the keto amide prepared in step I (40.0g, 0.143 mol) in dichloromethane (300.0 ml) was added slowly over a period of four hours at a temperature ranging from about -50C to about 0°C. The reaction mass was stirred for two hours. After completion of the reaction as determined by TLC, methanol was added dropwise to the reaction mass. Subsequently 5% hydrogen peroxide solution (80.0 ml) and 4N sulfuric acid (6.0 ml) were added to the reaction mixture and stirred for 15 minutes. The separated organic layer was washed with 2N sulfuric acid (80.0 ml) and 5% sodium sulfite (100.0 ml) water (100.0 ml) and brine solution (100.0ml). The organic layer was dried over anhydrous sodium sulfate and distilled under reduced pressure to provide the alcohol as an oil (38.Og).
[0020] IR(Cm"1): 3375, 2967, 2909, 2862, 1622, 1507, 1439, 1280, 1244, 1210,
1160, 1116, 1028, 852. 1H NMR (CDCl3) (δ ppm): 1.8(4H), 2.4(2H), 3.4(2H), 3.6(6H), 4.8(1H), 7.0(2H), 7.3(2H). (M+l): 282.2.
EXAMPLE 3
Step III: Synthesis of the Benzyl Protected Amide
[0021] To a solution of the alcohol prepared in step II (30.Og5 0.11 mol) in tetrahydrofuran (THF) (240.0 ml) maintained under nitrogen atmosphere, sodium hydride (5.5g, 0.138 mol) was added at a temperature of about O0C. Benzyl bromide (20.4g, 0.12 mol) was added slowly to the reaction mass at a temperature of about 00C. After completion of the addition, the reaction mass was stirred for 24 hours at room temperature. After completion of the reaction as determined by TLC, the reaction mass was cooled to O0C and water (30.0 ml) was added slowly. The reaction mixture was brought to room temperature and the solvent was distilled off under reduced pressure to get a residue. Water (200.0 ml) was added to the residue and extracted with ethyl acetate (3 X 200.0 ml). The ethyl acetate layer was washed with water (250.0 ml), brine (250.0 ml) and dried over anhydrous sodium sulfate. The organic layer was evaporated to yield the benzyl protected amide (38.Og).
[0022] IR(Cm"1): 3400, 3008, 2925, 2860, 2398, 1640, 1508, 1435, 1219, 1116,
837, 756, 699. 1H NMR (CDCl3) (δ ppm): 1.-6-2.0(4H), 2.3(2H), 3.4(2H), 3.6(6H), 4.2- 4.6(3H), 7.0(2H), 7.3(7H). (M+l):372.3.
EXAMPLE 4
Step IV: Synthesis of the Carboxylic Acid
[0023] The benzyl protected amide prepared in step III (40.Og, 0.11 mol), 95% ethanol (600.0 ml) and potassium hydroxide (30.0g, 0.54 mol) were taken in a IL round- bottom flask and refluxed at a temperature of about 780C for about 48 hours. After completion of the reaction as determined by TLC, the solvent was distilled out under reduced pressure. Water (400.0 ml) was added to the residue and extracted with dichloromethane (200.0 ml) to remove the organic impurities. The aqueous layer was cooled to a temperature ranging from about 0°C to about 50C and adjusted the pH to about 2.0 with concentrated HCl. The aqueous layer was extracted with ethyl acetate (2 X 200.0 ml). The ethyl acetate layer was washed with water (200.0 ml) and brine (200.0 ml). The organic layer was dried over anhydrous sodium sulfate. The organic layer was evaporated to yield the carboxylic acid as a liquid (17.Og).
[0024] IR(Cm"1): 3064, 3032, 2929, 2867, 1709, 1604, 1508, 1454, 1413, 1222,
1156, 1096, 836, 736. 1H NMR (CDCl3) (δ ppm): 1.5-2.0(5H), 2.3(2H), 4.2-4.4(3H), 7.0(2H), 7.3(7H). (M-l):301.3.
EXAMPLE 5 Step V: Synthesis of the Azetidinone
Preparation of acid chloride
[0025] DMF (1.5 ml, 0.017mol) and thionyl chloride (1.5 ml, 0.017mol) were added to a solution of the carboxylic acid prepared in step IV (5.0g, 0.02 mol) in dichloromethane (20.0 ml) maintained at a temperature of about 0°C under nitrogen atmosphere. The reaction mass was stirred and raised to a temperature ranging from about 20°C to about 25°C and maintained for 2.0 hours. Formation of β-Lactam
[0026] N,N'-Diisopropyl ethylamine (10.0ml, 0.06 mol) and triethylamine (1.0ml,
0.007 mol) were added to a solution of the imine of formula 7 above (2.5g, 0.008 mol) in toluene (100.0ml). The reaction mass was heated to reflux and the solution containing the acid chloride from above was added to the reaction mixture slowly over a period of about 2.0 hours. After completion of the addition, the reaction mass was maintained under reflux (a temperature ranging from about 1100C to about 112°C) for two hours. After completion of the reaction as determined by TLC, the reaction mass was cooled to a temperature of about 00C and IN HCl (100.0 ml) was added slowly and stirred for 15 minutes. The toluene layer was separated and washed with IN HCl (100.0 ml), water (2 X 100.0 ml) and brine (100.0 ml). The organic layer was dried over anhydrous sodium sulfate and evaporated to yield the azetidinone as a mixture of diastereomers (3.Og). [0027] IR(Cm'1): 2925, 2855, 1747, 1604, 1509, 1222, 1026. (M+l):590.8.
EXAMPLE 6
Step VI: Deprotection of Azetidinone to Yield Ezetimibe
[0028] A solution of the azetidinone prepared in step V (3.0g) in ethyl acetate
(100.0 ml) and methanol (50.0 ml) was hydrogenated over 10% Pd-C (1.Og) for 10.0 hours. After completion of the reaction as determined by TLC5 the reaction mass was filtered through a hy-flo bed. After evaporation, the ethyl acetate layer was recrystallized with methanol to yield ezetimibe.
[0029] IR(Cm'1): 3265, 2913, 1717, 1602, 1614, 1591, 1510, 1403, 1221, 1066,
831. 1H NMR (CDCl3) (δ ppm): 1.8-2.0(4H), 3.1(1H)3 4.5(1H), 4.8(1H), 5.3(1H), 6.8(2H), 7.1-7.4(1OH),9.6(1H).
EXAMPLE 7 Preparation of 4-(4-fluorobenzoyl) butyric acid
Figure imgf000013_0001
[0030] To anhydrous AlCl3 (250.Og, 1.87 mol) kept in a dry flask fluorobenzene
(307.5 g:3.2 moles) was added. The reaction mass was cooled to a temperature of about 5°C and a suspension of glutaric anhydride (0.86 mol) in fluorobenzene (400.0 ml, 4.3 mol) was added dropwise. After completion of the addition, the reaction mass was brought to room temperature and maintained for 2 hours. On completion of the reaction as determined by NMR, the reaction mass was cooled to a temperature ranging from about 0°C to about 30C and IN HCl (715.0 ml) was added below a temperature of about 20°C. The reaction mixture was poured into 2.3 L of ice- water suspension under stirring and the precipitated solids were filtered out. The solids were washed with water (500.0 ml) and treated with 5% NaHCO3 (3.2L) and filtered through a hy-flo bed. The solids were acidified with concentrated HCl (pH of about 1.0) at a temperature ranging from about O0C to about 5°C. The solids were precipitated out and the product was filtered and dried to yield 4-(4-fluorobenzoyl)-butyric acid (150.Og). Mp: 142-143°C. IR(Cm'1): 3073, 2967, 1698, 1672, 1597, 1509, 1414, 1258, 1241, 1165, 1075, 989, 839. 1H NMR (CDCl3) (δ ppm): 1.8(2H), 2.3(2H), 3.1(2H), 7.3(2H), 8.0(2H), 12.1(1H).
EXAMPLE 8
Step I: Preparation of the imine
Figure imgf000013_0002
Reaction of 4-fluoroaniline with 4-hydroxy benzaldehyde
[0031] 4-fluoroaniline (114.0 ml, 1.2 mol) was added dropwise to a solution of 4- hydroxy benzaldehyde (144.Og, 1.18 mol) in isopropyl alcohol (500.0 ml) maintained at 500C. The reaction mass was maintained for 2.0 hours at 50°C. After the completion of the reaction as determined by TLC, the separated solid was filtered, and the cake was washed with IPA (150.0 ml). The cake was dried for 6 hours at a temperature of about 60°C to furnish the imine (220.0g). Mp: 181-182°C. 1H NMR (DMSO d6) (δ ppm): 6.9(2H), 7.3(4H), 7.8(2H), 8.3(1H), 10.2(1H).
Step II: Protection of imine
[0032] Acetone (1200.0 ml), potassium carbonate (95.Og, 0.73 mol) and benzyl bromide (39.3g, 0.23 mol) were added to a dry 2L flask containing the imine prepared in step I (50.Og5 0.23 mol). The solution was maintained at reflux for 4.0 hrs. After completion of the reaction as determined by TLC, the reaction mass was brought to room temperature and filtered to separate the inorganic impurities. The solid obtained was washed with acetone (200.0 ml) and the washings were combined with the filtrate. The acetone layer was evaporated to get a residue which was dissolved in dichloromethane (600.0 ml). The dichloromethane layer was washed with water (2 X 250.0 ml). The dichloromethane layer on evaporation yielded the protected imine (58.0g). Mp: 135- 137°C. IR(Cm"1): 3446, 2867, 1604, 1508, 1249, 1219, 1165, 1003, 836. 1H NMR (CDCl3) (δ ppm): 5.2(2H), 7.1(4H), 7.2(2H)3 7.4(5H), 7.8(2H), 8.4(1H). 13C NMR (CDCl3) (δ ppm): 70.0, 115.0, 115.59, 115.88, 122.12, 122.23, 127.44, 128.11, 128.61, 129.25, 130.4, 136.34, 148.24, 148.28, 159.35, 161.36, 162.56. (M+l):306.2. [0033] It will be understood that various modifications may be made to the embodiments disclosed herein. Therefore the above description should not be construed as limiting, but merely as exemplifications of preferred embodiments. For example, the functions described above and implemented as the best mode for operating the present invention are for illustration purposes only. Other arrangements and methods may be implemented by those skilled in the art without departing from the scope and spirit of this invention. Moreover, those skilled in the art will envision other modifications within the scope and spirit of the claims appended hereto.

Claims

WHAT IS CLAIMED IS:
1. A process for preparing a compound of formula I:
Figure imgf000015_0001
the process comprising
(a) reacting an alcohol of formula III:
Figure imgf000015_0002
wherein R1 and R2 are independently hydrogen, hydrocarbons of from 1 to 20 carbon atoms or R1 and R2 together with the nitrogen atom to which they are bonded are joined together to form a substituted or unsubstituted heterocyclic group optionally containing one or more additional heterocyclic atoms, with a protecting group to provide a protected amide of formula IV:
Figure imgf000015_0003
(b) hydrolyzing the protected alcohol of step (a) with a strong base to provide a carboxylic acid of formula V:
Figure imgf000015_0004
(c) reacting an organic halide with the carboxylic acid of step (b) and an imine of the formula VI:
Figure imgf000016_0001
wherein Prot is a protecting group to provide an azetidinone of formula VII
Figure imgf000016_0002
(d) removing the protecting groups.
2. The process of Claim 1 , comprising
(a) reacting the alcohol of formula III with a benzyl halide in the presence of a base to provide a benzyl protected amide;
(b) hydrolyzing the benzyl protected amide product of step (a) with a strong base to provide a carboxylic acid;
(c) reacting the carboxylic acid product of step (b) with thionyl chloride and one or more bases and an imine of the formula VI wherein Prot is phenyl to provide an azetidinone; and
(d) debenzylation of the product of step (c) by hydrogenation.
3. The process of Claims 1 and 2, wherein in the alcohol of formula III R1 and R2 together with the nitrogen atom to which they are bonded form a substituted or unsubstituted heterocyclic group optionally containing one or more additional heterocyclic atoms.
4. The process of Claim 3, wherein the heterocyclic compound is a morpholine group.
5. The process of Claims 1 and 2, wherein in the alcohol of formula III R and R are independently selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, hexyl, cyclohexyl, heptyl, octyl, 2-ethylhexyl, nonyl, decyl, dodecyl, stearyl, oleyl, and phenyl.
6. The process of Claims 1-5, wherein in step (a) the protecting group is selected from the group consisting of benzyl bromide, benzyl chloride, and benzyl iodide.
7. The process of Claims 1-6, wherein in step (b) the base is selected from the group consisting of sodium t-butoxide, potassium t-butoxide, diisopropylamide, sodium hydride, potassium hydride, sodium methoxide, potassium methoxide and mixtures thereof.
8. The process of Claims 1-7, wherein the protected amide of step (b) is hydrolyzed in an ethanolic solution.
9. The process of Claim 1, wherein the organic halide is thionyl chloride.
10. The process of Claims 1-9, wherein step (c) is carried out in the presence of an aromatic hydrocarbon solvent.
11. The process of Claim 10, wherein the aromatic hydrocarbon solvent is selected from the group consisting of xylene, benzene, toluene, chlorobenzene and mixtures thereof.
12. The process of Claims 1-11, wherein the reaction of step (c) is carried out at reflux in the presence of at least one base.
13. The process of Claim 12, wherein the at least one base is selected from the group consisting of an organic amine, an alkoxide, an alkali metal hydroxide, an alkaline earth metal hydroxide and mixtures thereof.
14. The process of Claim 12, wherein the at least one base is selected from the group consisting of N,N'-diisopropyl ethylamine, triethylamine, sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide and mixtures thereof.
15. The process of Claims 1-14, wherein the reaction of step (c) is carried out at reflux in the presence of at least two bases.
16. The process of Claim 2, wherein the step of debenzylation of the azetidinone comprises hydrogenation with an alcoholic solution.
17. The process of Claim 16, wherein hydrogenation is with a methanolic solution and Pd/C under H2 at a pressure of about 6.5 Kg/cm2.
PCT/IB2005/002393 2005-08-09 2005-08-09 Process for the preparation of azetidinones WO2007017705A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IB2005/002393 WO2007017705A1 (en) 2005-08-09 2005-08-09 Process for the preparation of azetidinones

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2005/002393 WO2007017705A1 (en) 2005-08-09 2005-08-09 Process for the preparation of azetidinones

Publications (1)

Publication Number Publication Date
WO2007017705A1 true WO2007017705A1 (en) 2007-02-15

Family

ID=36087848

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/002393 WO2007017705A1 (en) 2005-08-09 2005-08-09 Process for the preparation of azetidinones

Country Status (1)

Country Link
WO (1) WO2007017705A1 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7842684B2 (en) 2006-04-27 2010-11-30 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitor activity
WO2010141494A2 (en) * 2009-06-02 2010-12-09 Codexis, Inc. Synthesis of ezetimibe
US7863265B2 (en) 2005-06-20 2011-01-04 Astrazeneca Ab 2-azetidinone derivatives and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia
US7871998B2 (en) 2003-12-23 2011-01-18 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity
US7893048B2 (en) 2005-06-22 2011-02-22 Astrazeneca Ab 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
US7906502B2 (en) 2005-06-22 2011-03-15 Astrazeneca Ab 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
WO2010113175A3 (en) * 2009-04-01 2011-04-21 Matrix Laboratories Ltd Enzymatic process for the preparation of (s)-5-(4-fluoro-phenyl)-5-hydroxy- 1morpholin-4-yl-pentan-1-one, an intermediate of ezetimibe and further conversion to ezetimibe
CN102731489A (en) * 2011-04-11 2012-10-17 天津药物研究院 Preparation method of key ezetimibe intermediate
WO2015039675A1 (en) 2013-09-23 2015-03-26 Pharmathen S.A. Novel process for the preparation of ezetimibe intermediates

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000034240A1 (en) * 1998-12-07 2000-06-15 Schering Corporation Process for the synthesis of azetidinones
WO2004099132A2 (en) * 2003-05-05 2004-11-18 Ranbaxy Laboratories Limited Process for the preparation of trans-isomers of diphenylazetidinone derivatives
WO2005044256A1 (en) * 2003-10-30 2005-05-19 Merck & Co., Inc. 2-azetidinones as anti-hypercholesterolemic agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000034240A1 (en) * 1998-12-07 2000-06-15 Schering Corporation Process for the synthesis of azetidinones
WO2004099132A2 (en) * 2003-05-05 2004-11-18 Ranbaxy Laboratories Limited Process for the preparation of trans-isomers of diphenylazetidinone derivatives
WO2005044256A1 (en) * 2003-10-30 2005-05-19 Merck & Co., Inc. 2-azetidinones as anti-hypercholesterolemic agents

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7871998B2 (en) 2003-12-23 2011-01-18 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity
US7863265B2 (en) 2005-06-20 2011-01-04 Astrazeneca Ab 2-azetidinone derivatives and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia
US7893048B2 (en) 2005-06-22 2011-02-22 Astrazeneca Ab 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
US7906502B2 (en) 2005-06-22 2011-03-15 Astrazeneca Ab 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
US7842684B2 (en) 2006-04-27 2010-11-30 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitor activity
WO2010113175A3 (en) * 2009-04-01 2011-04-21 Matrix Laboratories Ltd Enzymatic process for the preparation of (s)-5-(4-fluoro-phenyl)-5-hydroxy- 1morpholin-4-yl-pentan-1-one, an intermediate of ezetimibe and further conversion to ezetimibe
US9388440B2 (en) 2009-04-01 2016-07-12 Mylan Laboratories Limited Enzymatic process for the preparation of (S)-5-(4-fluoro-phenyl)-5-hydroxy-1morpholin-4-yl-pentan-1-one, an intermediate of Ezetimibe and further conversion to Ezetimibe
WO2010141494A2 (en) * 2009-06-02 2010-12-09 Codexis, Inc. Synthesis of ezetimibe
WO2010141494A3 (en) * 2009-06-02 2011-04-21 Codexis, Inc. Synthesis of ezetimibe
CN102731489A (en) * 2011-04-11 2012-10-17 天津药物研究院 Preparation method of key ezetimibe intermediate
CN102731489B (en) * 2011-04-11 2016-10-26 天津药物研究院有限公司 A kind of preparation method of key ezetimibe intermediate
WO2015039675A1 (en) 2013-09-23 2015-03-26 Pharmathen S.A. Novel process for the preparation of ezetimibe intermediates

Similar Documents

Publication Publication Date Title
WO2007017705A1 (en) Process for the preparation of azetidinones
US5306817A (en) Process for the stereospecific synthesis of azetidinones
CA2316360C (en) Process for production of donepezil derivative
US5561227A (en) Process for the stereospecific synthesis of azetidinones
JP3882224B2 (en) Method for producing paroxetine
JPS63139182A (en) Production of thiazolidinedione derivative
CA2554855A1 (en) Derivatives of alkylpiperazine- and alkylhomopiperazine- carboxylates, preparation method thereof and use of same as faah enzyme inhibitors
JP2002003370A5 (en)
EP1386607B1 (en) Process for the preparation of Donepezil
US20100249411A1 (en) Stereoselective Alkylation of Chiral 2-Methly-4 Protected Piperazines
JP3819532B2 (en) Piperidine derivatives and method for producing the same
JP2005047803A (en) Method for producing (3r,5s)-7-substituted-3,5-dihydroxyhept-6-enoic acid
JP4173599B2 (en) Process for producing 6-hydroxy-2-oxo-1,2,3,4-tetrahydroquinoline
JP4984676B2 (en) Preparation of aniline having benzyloxy group
CN102300839B (en) Method For Manufacturing Trans-{4-[(alkyl Amino) Methyl] Cyclohexyl} Acetic Ester
JP4507390B2 (en) 1-alkyl-1-substituted-3-organosulfonyloxyazetidinium salts and process for producing the same
JP2021526142A (en) Process for preparing 2- (1- (tert-butoxycarbonyl) piperidine-4-yl) benzoic acid
JP3529425B2 (en) Method for producing (S) -3-lower alkyl-2-piperazinone
JPWO2004099136A1 (en) Method for producing pyrrolidine derivative
JP3721540B2 (en) Pyrrolidine derivatives
JP4041922B2 (en) Method for producing pyrazole carboxylic acid ester derivative
JPH08333340A (en) Production of aminoethylpiperidine derivative
JP2004131486A (en) Method for producing n-alkoxycarbonylpiperidine derivative, raw material compound of the same and method for producing the same
JP4000758B2 (en) Process for producing 2- (5-halogeno-2-nitrophenyl) -2-substituted acetate derivative
KR100288404B1 (en) 2-Benzothiazolyl 4-amino-5-chloro-2-methoxythiobenzoate And Process For Preparing Cisapride Employing The Same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05775267

Country of ref document: EP

Kind code of ref document: A1